How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Effect of Resistant Starch on Insulin Sensitivity and Beta Cell Function in Subjects With Prediabetes

, the administration of a treatment that may affect the interpretation of the efficacy and safety data. Treatment with any oral antidiabetic medicinal product and / or herbal preparations / non-prescription medicines that may affect glycemic control within 12 weeks prior to screening. Chronic treatment with oral or parenteral corticosteroids (> 7 consecutive days of treatment) within 4 weeks prior to screening. Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion) within the last

2017 Clinical Trials

102. Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

(such as orlistat, sibutramine, rimonabant, phenylpropanol or chlorpheniramine) that promote weight loss within 3 months before study; Take any medications that may affect test results, such as antibiotics, non-steroidal anti-inflammatory drugs, antacids containing aluminum or magnesium, diuretics, anticoagulants, central nervous system inhibitors, systemic corticosteroids, medications to slow down the gastrointestinal motility, and any drug that may possibly affect the absorption of the drug within 2 weeks

2017 Clinical Trials

103. Targeted Enteral Nutrient Delivery: A Prospective Randomized Study

, and lithium) thioridazine, clozapine, Currently using or have used within three months prior to screening for this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine (either by prescription or as part of a clinical trial) Simultaneous participation in any other clinical trial of an investigational drug The receipt of any investigational product within four weeks prior to screening for this trial Herbal supplements or over-the-counter medications Diet attempts using herbal

2017 Clinical Trials

104. Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System

populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any surgery within 30 days of screening Those who currently donate blood, platelets, or plasma Any condition that, in the view of the PI or Co-I, places the subject at high risk or poor treatment and study compliance. We will also enroll 36 (...) ). Taking steroids or biologics: corticosteroids (prednisone); methotrexate, infliximib (Remicade®), etaneracept (Enbrel®); anakinra (Kineret®). Those who are currently donating blood, platelets, or plasma at the time of screening. Vulnerable populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any

2017 Clinical Trials

105. Fluorescent Imaging & Methylene Blue: Ureter Study

: Patient who is unable or unwilling to give informed consent Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. Significant renal or hepatic impairment. Any patients with previous allergies to Methylene Blue Any patients at risk of serotonin syndrome, including those taking serotonin reuptake inhibitors (SSRIs) or serotonin reuptake inhibitors (e.g. duloxetine, sibutramine, venlafaxine, clomipramine, imipramine) Patients with glucose-6-phosphate

2017 Clinical Trials

106. Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

of the study Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine) Clinically significant GI (Gastro-Intestinal) disease including inflammatory bowel disease, irritable bowel syndrome, celiac disease, dyspepsia, apparent diabetic gastro paresis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy and cholecystectomy) Subjects who are sexually active and have not been surgically sterilised must be informed that they and their partner use a highly

2017 Clinical Trials

107. Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

requirements for chemotherapy, radiotherapy or hormonal therapy. Participants must be willing to discontinue any use of NSAIDs like aspirin or ibuprofen until the tumor is removed Participants cannot be taking the following medications because of major pharmacokinetic interactions with celecoxib while being enrolled in the study: Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole, Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine, Ticlopidine

2017 Clinical Trials

108. Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness

, or participation within the last 3 months, in an organised weight loss programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee

2017 Clinical Trials

109. Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

or hypersensitivity to any of the ingredients in the test products. Cognitive impairment or any other reason to expect the patient would have difficulty complying with study protocol Excessive alcohol intake defined as greater than 3 units of alcohol per day. Use of weight loss drugs (e.g., lorcaserin [Belviq]; phentermine/topiramate [Qsymia], liraglutide [Saxenda], Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanol-amine], or similar over-the-counter medications) within 3 months of the screening

2017 Clinical Trials

110. Treatment of Pediatric Obesity: An Umbrella Systematic Review. Full Text available with Trip Pro

circumference, BMI, and diastolic blood pressure (low quality of evidence). Pharmacological interventions reduced BMI (metformin, sibutramine, orlistat) and waist circumference (sibutramine, orlistat) and increased high-density lipoprotein cholesterol (sibutramine) but also raised systolic and diastolic blood pressure (sibutramine). Surgical interventions (laparoscopic adjustable gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy) resulted in the largest BMI reduction (moderate quality

2017 Journal of Clinical Endocrinology and Metabolism

111. SNAP: a population health guide to behavioural risk factors in general practice

appropriate. For a small number of obese patients (BMI >30 or BMI >27 with other diseases) who do not respond, medical or surgical interventions may need to be considered. Drugs that may be added to education and behavioural interventions include orlistat and sibutramine for long term therapy, and phentermine and diethylpropion for short term use only. Small amounts of weight loss or lack of any increase can be viewed as successes with health gains likely. Any changes made must be able to be maintained

2014 The Royal Australian College of General Practitioners

112. Systematic review with meta-analysis: Orlistat reduces weight but its cost?effectiveness remains unclear

, sibutramine and … Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright information: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to Read the full text or download the PDF: Subscribe Log in Log

2013 Evidence-Based Nursing

113. Cost-effectiveness of pharmacotherapy to reduce obesity Full Text available with Trip Pro

Study objective This study evaluated the cost-effectiveness of pharmaceutical interventions, versus standard care, for obesity in Australian adults aged 20 years or older. Interventions Pharmaceutical care consisted of either 15mg sibutramine, once daily, or 120mg of orlistat, thrice daily. Patients were allowed one 12-month course of treatment. This was compared with usual care, with no drug treatment. Location/setting Australia/primary care. Methods Analytical approach: The authors used a Markov (...) not take their medication. Weight regain data were from the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) trial for sibutramine and were assumed to be the same for orlistat. It was assumed that none of the weight loss was permanent. Monetary benefit and utility valuations: Health-related quality of life utilities were calculated, for the nine disease states, using disability-adjusted life-year (DALY) weights from an Australian study. Measure of benefit: The DALYs averted were

2011 NHS Economic Evaluation Database.

114. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis

: sulfonylureas, meglitinides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, insulins and insulin analogues, alpha-glucosidase inhibitors, and weight-loss agents (orlistat and sibutramine). Outcomes of interest included glycated haemoglobin (HbA 1c ), hypoglycaemia, body weight, quality of life, long-term complications of diabetes, severe adverse events, and mortality. In included trials, the mean baseline glycated haemoglobin ranged from 6.6% to 10

2011 DARE.

115. Obesity and the Older Persons

, exacerbation of gout and sequelae of hypovolaemia (70). Anti-obesity drugs can be classified as fat-absorption altering (orlistat), thermogenesis increasing (ephedrine) and anorectic (sibutramine, topiramate, SSRIs such as sertraline or fluoxetine). They have been found to be safe and effective in younger adults in multiple randomised controlled trials. Currently, however, there is insufficient evidence to recommend the use of anti-obesity agents in the elderly. The Future In terms of weight loss

2011 Australian and New Zealand Society for Geriatric Medicine

116. Obesity

- release daily dizziness, mild increase in blood pressure and heart rate excreted by kidneys; pregnancy category B; requires blood- pressure monitoring Sibutramine Meridia (Abbott) Approved for weight loss No Inhibition of norepinephrine and serotonin reuptake 5, 10, or 15 mg/day 5% Mild increase in blood pressure and heart rate (rarely more severe), palpitations Pregnancy category C; requires blood- pressure monitoring Orlistat Xenical (Roche); Alli (GlaxoSmithKline) Approved for weight loss No Lipase (...) Organisation, 2011 • Approved for short-term use only; limited data suggest these stimulants may be effective for > 10 years. SibutramineSibutramine is modestly effective in reducing weight, with differing effects on cardiovascular risk and various adverse effect profiles. • Treatment with sibutramine reduced body weight but not blood pressure. • Randomized trials have shown a 5% greater weight reduction in comparison with placebo (but only short-term trials have been carried out; administration

2011 World Gastroenterology Organisation

117. Highlights of the year in Evidence-Based Medicine

as likely to have an x-ray, ultrasound or imaging after seeing a self-employed urologist as opposed to a Staying on the diagnostic theme, we learnt we should not be pooling diagnostic likelihood ratios in . , and Docs suggested women were hitting the pause button on , which sounded very much like the HRT story. On the drug front, we managed to give out 300,000 prescriptions for sibutramine in the . Put me in charge of the drug budget, I’ll show you some cuts. Yet, nearly 1 in 10 prescribed meds were

2011 TrustTheEvidence

118. Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side-Effect Profiles. (Abstract)

(PPA)], excess non-fatal cardiovascular events (sibutramine), and neuro-psychiatric issues (rimonabant; approved in Europe, but not in the USA). This negative experience has helped mould the current drug development and approval process for new anti-obesity drugs. Differences between the US Food and Drug Administration (FDA) and the European Medicines Agency, however, in perceptions of risk-benefit considerations for individual drugs have resulted in discrepancies in approval and/or withdrawal

2016 obesity & metabolism

119. [Acupuncture for treatment of simple obesity and its effect on serum leptin level of the patient]. (Abstract)

(Shenmen, Endocrine, etc. were selected); the patients in the control group were treated with oral administration of sibutramine. The serum leptin level before and after treatment were determined and the therapeutic effect in reducing body weight was assessed.The total effective rate was 88.0% in the acupuncture group and 80. 0% in the control group, with no significant difference between the two groups (P>0.05); after treatment, the serum leptin level in both the two groups decreased significantly (P

2016 Zhongguo zhen jiu = Chinese acupuncture & moxibustion Controlled trial quality: uncertain

120. Analysis of trace amounts of adulterants found in powders/supplements utilizing Raman spectroscopy coupled to direct analyte-probed nanoextraction-nanospray ionization-mass spectrometry Full Text available with Trip Pro

analysis via nanospray of the particulate of interest eliminates time consuming chromatographic techniques prior to mass spectrometry analysis. This coupled technique combines rapid Raman spectroscopy techniques with direct mass spectrometry to confirm the presence of an adulterant. This technique was applied to an FDA supplied test sample, in which sibutramine, phenolphthalein, and melamine were confirmed to be present.

2016 Analytical methods : advancing methods and applications

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>